Avalyn Pharma Inc (AVLN) AI Stock Analysis

8 Followers

Avalyn Pharma Inc

(NASDAQ:AVLN)

Select Model

Rating:48Neutral

Price Target:$30.00▼(-0.92% Downside)

Action:initiatedcoverage

Date:11/13/26

The score is held down primarily by weak financial performance (pre-revenue status, widening losses, accelerating cash burn, and deeply negative equity). Technicals provide partial offset with positive trend and momentum signals, while valuation remains difficult to support due to negative earnings and no dividend yield data.

Positive Factors

Low Debt BurdenVery low debt limits interest obligations and reduces leverage-related pressure while Avalyn advances its clinical programs. Although the company remains financially fragile overall, modest borrowing preserves more flexibility than a heavily indebted balance sheet would provide.

Negative Factors

Pre-Revenue BusinessThe absence of revenue means Avalyn has not yet demonstrated commercial demand or an operating revenue base to fund development. Continued dependence on clinical progress and future financing leaves the business exposed if programs take longer or require more capital.

Avalyn Pharma Inc (AVLN) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $1.34B
Dividend Yield: ―
Average Volume (3M): 337.08K
Price to Earnings (P/E): -17.1
Beta (1Y): 0.58
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 55
Sector: General
Sector Strength: 55
Industry: Biotechnology

Avalyn Pharma Inc Business Overview & Revenue Model

Company Description

Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various o...

Avalyn Pharma Inc Financial Statement Overview

Summary

Financials are weak: the company is pre-revenue (zero revenue in 2024–2025) with widening losses (EBIT from -$57.1M to -$91.3M; net loss from -$49.7M to -$85.2M) and accelerating cash burn (operating cash flow from -$48.4M to -$81.5M; FCF from -$48.5M to -$81.8M). Balance sheet risk is elevated due to deeply negative and worsening equity (-$174.5M to -$238.7M), though low debt ($0 to $1.7M) is a relative positive.

Income Statement

12Very Negative

Balance Sheet

18Very Negative

Cash Flow

14Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024
Income Statement
Total Revenue	0	0	0
Gross Profit	-214.40K	0	0
EBITDA	-90.98M	-91.25M	-57.09M
Net Income	-85.46M	-85.20M	-49.74M
Balance Sheet
Total Assets	399.30M	148.88M	124.52M
Cash, Cash Equivalents and Short-Term Investments	327.46M	138.36M	110.63M
Total Debt	16.93M	1.67M	0
Total Liabilities	29.05M	387.54M	299.04M
Stockholders Equity	370.25M	-238.66M	-174.52M
Cash Flow
Free Cash Flow	-82.90M	-81.83M	-48.46M
Operating Cash Flow	-82.24M	-81.48M	-48.37M
Investing Cash Flow	-155.46M	10.06M	-91.47M
Financing Cash Flow	330.80M	99.79M	89.00K

Avalyn Pharma Inc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

AVLN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ONC	76Outperform	$47.82B	66.97	18.24%	―	33.13%	1272.97%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
NEUP	48Neutral	$13.96M	-0.35	-77.03%	―	―	―
AVLN	48Neutral	$1.36B	-17.11	-62.84%	―	―	―
KYNB	43Neutral	$14.54M	0.06	-605.53%	―	-91.38%	―
RNTX	43Neutral	$48.31M	-0.30	-234.45%	―	―	36.23%
BGMS	40Underperform	$4.70M	-0.27	-24.24%	―	2658.02%	97.18%

* General Sector Average

Performance Comparison

AVLN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
AVLN	Avalyn Pharma Inc	30.28	0.79	2.68%
BGMS	Bio Green Med Solution, Inc.	0.64	-0.57	-47.11%
KYNB	Kyntra Bio, Inc.	3.44	-5.26	-60.46%
ONC	BeOne Medicines	416.54	39.91	10.60%
RNTX	Rein Therapeutics, Inc	0.55	-0.67	-54.75%
NEUP	Neuphoria Therapeutics Inc.	2.55	-2.15	-45.74%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026

Avalyn Pharma Inc AI Stock Analysis